TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Provided By GlobeNewswire
Last update: Nov 1, 2023
Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment received from Neuraxpharm
33.64
-0.22 (-0.65%)
Find more stocks in the Stock Screener
TGTX Latest News and Analysis
8 days ago - ChartmillApplying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX)A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing?
